Skip to main content
. 2023 Dec 5;13(1):178. doi: 10.1038/s41408-023-00949-w

Table 2.

Adverse events during induction treatment, n (%).

Total
N = 176
ATO
N = 85
RIF
N = 91
p
Differentiation syndrome
 Moderate 11 (6.3) 7 (8.2) 4 (4.4) 0.293
 Severe 1 (0.6) 1 (1.2) 0 (0) 0.483
 Infection/FUO 134 (76.1) 65 (76.5) 69 (75.8) 0.920
 PCT 28 (15.9) 13 (15.3) 15 (16.5) 0.829
Coagulopathy events
 Hemorrhage 8 (4.5) 3 (3.5) 5 (5.5) 0.721
 Thrombosis 3 (1.7) 3 (3.5) 0 (0) 0.111
Liver
 Grade 1–2 19 (10.8) 11 (12.9) 8 (8.8) 0.375
 Grade 3–4 0 (0) 0 (0) 0 (0) -
Cardiac
 Grade 1–2 1 (0.6) 1 (1.2) 0 (0) 0.483
 Grade 3–4 1 (0.6) 1 (1.2) 0 (0) 0.483
Gastrointestinal reaction
 Grade 1–2 49 (27.8) 25 (29.4) 24 (26.4) 0.653
 Grade 3–4 0 (0) 0 (0) 0 (0) -
 Rash 11(6.3) 5 (5.9) 6 (6.6) 0.845
 Hyperlipemia 1(0.6) 0 (0) 1 (1.1) 1.000

FUO fever of unknown origin, PCT pseudotumor cerebri.